SCHEMBL30983424

SCHEMBL30983424

CN1CCN(C(=O)COc2ccc(-c3nc4c(OC5(C)CC5)ncnc4n3Cc3ccccc3)c(Cl)c2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1D P28221 4/20 0.43
▸ HTR1B P28222 4/20 0.43
▸ POLB P06746 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ GPR183 P32249 3/20 0.40
▸ CNR1 P21554 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HTR1A P08908 3/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983534 0.92 GPR183 (0.39) HTR1DHTR1BALDH1A1KDM4EMEN1
SCHEMBL30983954 0.89 PLA2G2A (0.39) KDM4EKMT2ACNR1MCL1
SCHEMBL30983924 0.88 PLA2G2A (0.38) KMT2ACNR1
SCHEMBL30983822 0.87 DRD2 (0.42) ALDH1A1KDM4EMEN1KMT2ACNR1
SCHEMBL30984034 0.87 PIK3CD (0.37) POLBALDH1A1KDM4EMEN1KMT2A
SCHEMBL30983512 0.87 KMT2A (0.36) POLBMEN1KMT2ASMN1; SMN2CNR1
SCHEMBL30983502 0.87 NPC1 (0.38) POLBALDH1A1KDM4EMEN1KMT2A
SCHEMBL30983498 0.86 MAOB (0.40) ALDH1A1KDM4EKMT2ACNR1GAA
SCHEMBL30983449 0.85 ALDH1A1 (0.42) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL31321937 0.85 PLA2G2A (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR1D 4542/4885HTR1B 4365/4885POLB 3/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HTR1D 4542/4885HTR1B 4365/4885POLB 3/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HTR1D 4542/4885HTR1B 4365/4885POLB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback